CinRx Pharma

About CinRx Pharma

CinRx Pharma is a biotechnology company focused on advancing a portfolio of high-impact medicines. They invest in and guide drug candidates through development, emphasizing therapies that can transform treatment and significantly improve patients' quality of life.

Products & Services

CinFina Pharma:Focused on treatments for metabolic diseases.

CinDome Pharma:Developing treatments for gastroparesis, including Deudomperidone (CIN-102) in Phase 2 clinical trials.

vTv Therapeutics:Developing therapies for Type 1 Diabetes.

Specialties

Metabolic Diseases Gastroparesis Hypertension Type 1 Diabetes Neurodegenerative Diseases Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Additional Financing T: - FT: Additional Financing	A: 73000000 MR: - FA: $73 million FAN: 73000000	D: 2024-05-30 FD: 2024-05-30	1 investors

Additional Financing Latest

2024-05-30

$73.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jon Isaacsohn

Founder & Chief Executive Officer

B

Brian Murphy

Chief Medical Officer

M

Mary Bond

Chief Translational Science Officer

S

Sally Dressman

Chief Administrative Officer

B

Beth Moriarity

Clinical Operations

S

Smita Singh

Clinical Operations

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

CinRx Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised